Source: Health Products Regulatory Authority (IE) Revision Year: 2020 Publisher: Rowex Ltd, Newtown, Bantry, Co. Cork, Ireland
SUMATRAN 50 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Pink, oblong tablet with a break notch on both sides. The tablet can be divided into equal doses. |
Each tablet contains 50 mg sumatriptan (as succinate).
Excipients with known effect: Each tablet contains 176.20 mg lactose (as monohydrate) and up to 0.15 micrograms of sulphites per tablet.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Sumatriptan |
Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D) receptor agonist with no effect on other 5HT receptor (5-HT2 - 5-HT7) subtypes. The vascular 5-HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction. |
| List of Excipients |
|---|
|
Ammonium methacrylate copolymer type A |
The tablets are packed in aluminium/aluminium blister strips and inserted in a cardboard carton.
2, 3, 4, 6, 8, 12, 18, 20, 24, 30, 50, 100 tablets.
Not all pack sizes may be marketed.
Rowex Ltd, Newtown, Bantry, Co. Cork, Ireland
PA0711/081/001
Date of first authorisation: 27 January 2006
Date of last renewal: 1 December 2009
| Drug | Countries | |
|---|---|---|
| SUMATRAN | Australia, Ireland, Singapore |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
